Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ODI Pharma AB's revenue for the
three
months ended in Mar. 2026 was kr12.71 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was kr29.62 Mil.
ODI Pharma AB's Revenue per Share for the
three
months ended in Mar. 2026 was kr0.69.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.62.
During the past 12 months, the average Revenue per Share Growth Rate of ODI Pharma AB was 134.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 100.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 7 years, ODI Pharma AB's highest 3-Year average Revenue per Share Growth Rate was 100.40% per year. The lowest was 100.40% per year. And the median was 100.40% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
ODI Pharma AB Revenue Related Terms
ODI Pharma AB Revenue Historical Data
* Premium members only.
The historical data trend for ODI Pharma AB's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ODI Pharma AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ODI Pharma AB Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ODI Pharma AB's Revenue distribution charts can be found below:
* The bar in red indicates where ODI Pharma AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr29.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ODI Pharma AB (XSAT:ODI) has a Revenue of kr29.62 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on ODI Pharma AB and its competitors.
Is ODI Pharma AB's Revenue too high?
ODI Pharma AB's current Revenue is kr29.62 Mil. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's Revenue compare to ZTS and UTHR?
ODI Pharma AB's Revenue of kr29.62 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on ODI Pharma AB and its competitors. ODI Pharma AB's current Revenue is kr29.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.71, compared to a current price of kr2.36 — trading 75.7% below its estimated fair value. The current Revenue is kr29.62 Mil. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current Revenue is kr29.62 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?
Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued.
The current stock price of kr2.36 is trading 75.7% below its estimated GF Value™ of kr9.71.
GuruFocus considers ODI Pharma AB to be Significantly Undervalued.
Key valuation signals for XSAT:ODI:
Revenue: kr29.62 Mil
GF Value™: kr9.71 vs. price of kr2.36 (75.7% below fair value)
No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ODI has been successfully added to your 
